抗炎保肝药在自身免疫性肝炎治疗中的应用进展

摘要

自身免疫性肝炎(AIH)是首个经试验证实糖皮质激素治疗有效的肝脏疾病,其标准治疗为激素联合硫唑嘌呤.考虑到部分患者达不到免疫抑制治疗指征,以及长期应用免疫抑制治疗不良反应较多,故有必要规范合理的应用抗炎保肝药以使免疫抑制剂的剂量最小化,控制肝脏炎症,减少肝细胞的破坏,延缓疾病的进展.综述了抗炎保肝药在AIH治疗中的应用进展,以帮助临床医生进行合理决策.%Autoimmune hepatitis (AIH) is the first liver disease which has proved responsive to gluc()orticoids,and the standard therapeutic method is hormone combined with azathioprine.Given that some patients fail to reach the standard of immunosuppressive therapy,and the long-term use of immunosuppressive therapy has many adverse effects,it is necessary to reasonably use anti-inflammatory and liver-protecting drugs to minimize the dose of immunosuppressants,control liver inflammation,reduce the damage of liver cells,and delay the progression of the disease.This paper reviews the advances in the application of anti-inflammatory and liver-protecting drugs in the treatment of AIH,in order to help clinicians make rational decisions.